Trust Company of Vermont’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $45.3K | Sell |
247
-74
| -23% | -$13K | ﹤0.01% | 579 |
|
|
2025
Q3 | $49.3K | Sell |
321
-125
| -28% | -$18.9K | ﹤0.01% | 557 |
|
|
2025
Q2 | $62.3K | Hold |
446
| – | – | ﹤0.01% | 517 |
|
|
2025
Q1 | $65.6K | Sell |
446
-156
| -26% | -$22.6K | ﹤0.01% | 480 |
|
|
2024
Q4 | $78.9K | Buy |
602
+287
| +91% | +$40.2K | ﹤0.01% | 461 |
|
|
2024
Q3 | $49.1K | Sell |
315
-821
| -72% | -$133K | ﹤0.01% | 521 |
|
|
2024
Q2 | $177K | Sell |
1,136
-410
| -27% | -$61.7K | 0.01% | 329 |
|
|
2024
Q1 | $209K | Buy |
1,546
+890
| +136% | +$118K | 0.01% | 305 |
|
|
2023
Q4 | $88.3K | Sell |
656
-1,871
| -74% | -$243K | 0.01% | 367 |
|
|
2023
Q3 | $342K | Sell |
2,527
-208
| -8% | -$28.4K | 0.02% | 244 |
|
|
2023
Q2 | $391K | Hold |
2,735
| – | – | 0.03% | 239 |
|
|
2023
Q1 | $380K | Buy |
2,735
+83
| +3% | +$11.2K | 0.03% | 251 |
|
|
2022
Q4 | $360K | Buy |
2,652
+42
| +2% | +$5.27K | 0.03% | 244 |
|
|
2022
Q3 | $287K | Buy |
2,610
+60
| +2% | +$7.61K | 0.02% | 257 |
|
|
2022
Q2 | $337K | Buy |
2,550
+25
| +1% | +$3.28K | 0.03% | 242 |
|
|
2022
Q1 | $335K | Hold |
2,525
| – | – | 0.02% | 255 |
|
|
2021
Q4 | $295K | Hold |
2,525
| – | – | 0.02% | 280 |
|
|
2021
Q3 | $303K | Buy |
2,525
+550
| +28% | +$64K | 0.02% | 265 |
|
|
2021
Q2 | $237K | Sell |
1,975
-150
| -7% | -$16.5K | 0.02% | 293 |
|
|
2021
Q1 | $211K | Hold |
2,125
| – | – | 0.02% | 296 |
|
|
2020
Q4 | $212K | Sell |
2,125
-172
| -7% | -$18.2K | 0.02% | 284 |
|
|
2020
Q3 | $252K | Buy |
2,297
+288
| +14% | +$32K | 0.02% | 248 |
|
|
2020
Q2 | $212K | Buy |
2,009
+100
| +5% | +$10.3K | 0.02% | 269 |
|
|
2020
Q1 | $171K | Buy |
1,909
+300
| +19% | +$28.2K | 0.02% | 299 |
|
|
2019
Q4 | $161K | Hold |
1,609
| – | – | 0.01% | 342 |
|
|
2019
Q3 | $143K | Sell |
1,609
-185
| -10% | -$16K | 0.01% | 363 |
|
|
2019
Q2 | $148K | Buy |
1,794
+44
| +3% | +$3.45K | 0.01% | 360 |
|
|
2019
Q1 | $141K | Buy |
1,750
+105
| +6% | +$8.28K | 0.01% | 359 |
|
|
2018
Q4 | $125K | Hold |
1,645
| – | – | 0.01% | 357 |
|
|
2018
Q3 | $130K | Buy |
1,645
+375
| +30% | +$28.4K | 0.01% | 378 |
|
|
2018
Q2 | $89K | Buy |
1,270
+85
| +7% | +$6.12K | 0.01% | 429 |
|
|
2018
Q1 | $83K | Hold |
1,185
| – | – | 0.01% | 415 |
|
|
2017
Q4 | $82K | Hold |
1,185
| – | – | 0.01% | 429 |
|
|
2017
Q3 | $81K | Hold |
1,185
| – | – | 0.01% | 426 |
|
|
2017
Q2 | $81K | Hold |
1,185
| – | – | 0.01% | 441 |
|
|
2017
Q1 | $74K | Sell |
1,185
-83
| -7% | -$4.83K | 0.01% | 439 |
|
|
2016
Q4 | $70K | Buy |
1,268
+26
| +2% | +$1.48K | 0.01% | 435 |
|
|
2016
Q3 | $82K | Sell |
1,242
-194
| -14% | -$12.7K | 0.01% | 370 |
|
|
2016
Q2 | $86K | Buy |
1,436
+55
| +4% | +$3.19K | 0.01% | 334 |
|
|
2016
Q1 | $78K | Sell |
1,381
-215
| -13% | -$12.9K | 0.01% | 339 |
|
|
2015
Q4 | $109K | Buy |
1,596
+57
| +4% | +$3.74K | 0.02% | 309 |
|
|
2015
Q3 | $98K | Sell |
1,539
-440
| -22% | -$28.9K | 0.02% | 308 |
|
|
2015
Q2 | $126K | Buy |
1,979
+139
| +8% | +$9.52K | 0.02% | 283 |
|
|
2015
Q1 | $126K | Hold |
1,840
| – | – | 0.02% | 281 |
|
|
2014
Q4 | $129K | Hold |
1,840
| – | – | 0.02% | 280 |
|
|
2014
Q3 | $131K | Buy |
1,840
+415
| +29% | +$30.4K | 0.02% | 273 |
|
|
2014
Q2 | $105K | Hold |
1,425
| – | – | 0.02% | 280 |
|
|
2014
Q1 | $92K | Sell |
1,425
-2,723
| -66% | -$176K | 0.02% | 294 |
|
|
2013
Q4 | $246K | Sell |
4,148
-264
| -6% | -$14.3K | 0.04% | 202 |
|
|
2013
Q3 | $229K | Buy |
4,412
+963
| +28% | +$48.4K | 0.04% | 202 |
|
|
2013
Q2 | $163K | Buy |
+3,449
| New | +$176K | 0.03% | 224 |
|
Other funds holding AZN
Trust Company of Vermont's AZN Position: Q4 2025 in Review
Trust Company of Vermont reduced its AstraZeneca (AZN) stake by 23% in Q4 2025, selling an estimated $13K and leaving 247 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #579.
Trust Company of Vermont first reported a position in AZN in Q2 2013 and has held it in 51 quarters since. The position peaked at $391K in Q2 2023. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.
- Trust Company of Vermont held 247 shares of AstraZeneca worth $45.3K as of Q4 2025.
- Trust Company of Vermont sold 74 AstraZeneca shares in Q4 2025, an estimated $13K.
- AstraZeneca made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #579 holding.
- Trust Company of Vermont first reported a position in AstraZeneca in Q2 2013 and has held it in 51 quarters since.
- Trust Company of Vermont's AstraZeneca position peaked at $391K in Q2 2023.
- 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.
Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.